CD8A and neoplasm: Further, by using PVRIG-deficient mice and self-generated anti-mouse PVRIG mAb, we showed that PVRIG deficiency or PVRIG blockade (both early and late treatments) could reduce the tumor size and prolong the survival of tumor-bearing mice through inhibiting NK cell and CD8+ T cell exhaustion.